American Association for Cancer Research
crc-22-0301_fig5.png (102.63 kB)

FIGURE 5 from Genome-wide CRISPR Screen Reveals RAB10 as a Synthetic Lethal Gene in Colorectal and Pancreatic Cancers Carrying SMAD4 Loss

Download (102.63 kB)
posted on 2023-05-04, 14:20 authored by Hélène Erasimus, Vanessa Kolnik, Frédéric Lacroix, Sukhvinder Sidhu, Stéphane D'Agostino, Olivier Lemaitre, Alexandre Rohaut, Isabelle Sanchez, Gilbert Thill, Michel Didier, Laurent Debussche, Christophe Marcireau

Association of the expression level of Rab10 with the CNA of SMAD4 in pancreatic and colorectal tumors. Violin plot showing the expression level of Rab10 relative to SMAD4 CNAs in colorectal cancer (TCGA, PanCancer Atlas, 524 patients, *, P < 0.05; A) and in pancreas cancers (pancreatic adenocarcinoma; TCGA, PanCancer Atlas, 168 patients; B). For both panels, we performed a Kruskal–Wallis one-way ANOVA, followed by a post hoc Dunnett test to compare each group versus the “SMAD4 deep deletion” group.


Sanofi (Sanofi US)



This study identified and validated RAB10 as new synthetic lethal gene with SMAD4. This was achieved by conducting a whole-genome CRISPR screens in different colorectal and pancreatic cell lines. A future RAB10 inhibitors could correspond to a new therapeutic solution for patients with cancer with SMAD4 deletion.